Automated Scientific Intelligence for Pharma R&D

The Customer

Company B is one of the world’s largest pharmaceutical and diagnostics companies, with a global R&D organisation spanning oncology, immunology, neuroscience, and infectious disease. Its R&D, Business Development, and Competitive Intelligence teams are responsible for tracking scientific developments across dozens of therapeutic areas simultaneously, monitoring competitor pipelines, identifying emerging technologies, and scouting academic partnerships against rivals including Novartis, Roche, AstraZeneca, Pfizer, Merck, Bristol Myers Squibb, and a rapidly expanding wave of biotech companies.

The Short Version

• The challenge: Company B’s R&D and Business Development teams monitor scientific developments across preprint servers, pharma news, sector intelligence feeds, and a constant stream of pipeline moves through a patchwork of manual searches, Excel trackers, and quarterly reports that are outdated before they are distributed. The result is a structural lag: breakthrough research surfaces weeks after it first appears, competitor moves are discovered from press releases rather than primary signals, and emerging platform technologies gain traction before the team has a chance to act.
• The solution: ScaLabs.AI continuously monitors 16 curated live public sources covering preprint servers, pharma and biotech news, and sector intelligence feeds, and auto-generates structured intelligence products on a fixed weekly cadence.
• The impact: A university lab posts unpartnered CAR-T delivery data on bioRxiv on a Tuesday — cited in three investor notes by Friday. A next-generation oral degrader appears as a late-breaking abstract with no industry partner listed. An oral small molecule trend builds silently across three deals and four preprints over six weeks without anyone connecting the dots. ScaLabs.AI detects each signal at the moment it appears and delivers a structured, source-cited brief to the right teams before the working week begins.

01 — The Problem

R&D Intelligence That Arrives Too Late Is Not Intelligence

A pharma company’s R&D and Business Development teams track scientific developments across preprint servers, clinical news, deal announcements, and sector trend reports simultaneously, every week. Four analysts spent 15 or more hours weekly on manual searches, Excel trackers, and quarterly reports that were outdated before they were distributed.

A competitor’s unpartnered gene delivery preprint appeared on bioRxiv on a Tuesday. By Friday it had been cited in three investor notes. The team found it the following week — after the competitor had already initiated a partnership conversation with the same academic lab.

Three failure modes repeated every quarter:

• Lag: Breakthrough research surfaced weeks after it first appeared on preprint servers.
• Blindspot: Competitor moves were discovered from press releases, not primary signals.
• Late pivot: Emerging platform technologies built momentum before the team had time to act.

The problem is not effort — it is architecture. No analyst can read hundreds of preprints, track 16 intelligence sources, and identify cross-source patterns simultaneously. The task demands automation.

02 — The Solution

One Brief. Every Monday. Zero Manual Work.

ScaLabs.AI continuously monitors 16 curated live public sources across three coverage layers and auto-generates four structured intelligence outputs on a fixed weekly cadence, filtered by therapeutic area.

Therapeutic Area Filter

The platform is configured around the company’s active areas of focus. This case study applies an oncology filter, but the same architecture deploys for any area: immunology, neuroscience, rare disease, infectious disease, or custom combinations set at onboarding.

16 Sources Across 3 Coverage Layers

Layer 1 — Preprint Servers (monitored daily)

Layer 2 — Pharma & Biotech News Intelligence (monitored daily)

Layer 3 — Sector Intelligence & Research Trend Tracking (monitored weekly)

03 — The Intelligence Products: 4 Auto-Generated Outputs

Structured, Source-Cited, Ready for Leadership Review

The weekly brief is auto-generated and delivered formatted every Monday at 07:00 CET. No analyst preparation is required after initial setup.

04 — Real Output: Week of May 1–8, 2026

Oncology Filter — Actual Brief, Actual Sources

The following is a real, data-populated brief built from live public sources for the reporting period May 2–8, 2026. Every item was pulled automatically from the monitored source list. Nothing was added by an analyst.

05 — The Impact: Before vs. After ScaLabs.AI

06 — Why This Prototype Is Production-Ready Today

• Every source is live right now. All 16 URLs across S1–S16 are public, continuously updated, and require no login or proprietary data access.
• The unpartnered signal changes the conversation. Ask any BD director: “A university lab just posted CAR-T delivery data on bioRxiv with no industry partner listed. Do you want to know about it before your competitors do?”
• The ROI is immediate and personal. A team spending 15 hours per week on manual monitoring gets back hundreds of hours per year — a number that is immediately legible to every R&D and BD professional in the room.
• The output requires zero post-processing. The weekly brief arrives formatted, source-cited, and ready for leadership review every Monday morning.

Ready to Put Your Competitor Intelligence on Autopilot?

ScaLabs.AI monitors every relevant public source continuously, preprint servers, pharma news and sector intelligence, and delivers structured, source-cited scientific intelligence to the right teams at the right time, automatically.

No consultants. No lag. No blind spots.

This prototype is built entirely from publicly available, live sources. All 16 intelligence sources referenced are accessible today and ready to deploy in under an hour.